Palisade Capital Management LP Takes Position in Bruker Corporation $BRKR

Palisade Capital Management LP acquired a new position in shares of Bruker Corporation (NASDAQ:BRKR) in the 2nd quarter, Holdings Channel reports. The fund acquired 210,024 shares of the medical research company’s stock, valued at approximately $12,639,000.

A number of other hedge funds have also modified their holdings of BRKR. Royal Bank of Canada lifted its stake in Bruker by 8.3% in the 1st quarter. Royal Bank of Canada now owns 123,336 shares of the medical research company’s stock valued at $5,148,000 after acquiring an additional 9,501 shares in the last quarter. Jacobs Levy Equity Management Inc. bought a new position in shares of Bruker during the 1st quarter worth approximately $262,000. Goldman Sachs Group Inc. raised its holdings in shares of Bruker by 107.3% in the first quarter. Goldman Sachs Group Inc. now owns 1,465,319 shares of the medical research company’s stock valued at $61,162,000 after purchasing an additional 758,301 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Bruker by 2.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 366,204 shares of the medical research company’s stock valued at $15,285,000 after purchasing an additional 9,235 shares during the last quarter. Finally, Focus Partners Wealth lifted its position in shares of Bruker by 115.0% in the first quarter. Focus Partners Wealth now owns 11,232 shares of the medical research company’s stock worth $469,000 after purchasing an additional 6,008 shares in the last quarter. 79.52% of the stock is currently owned by institutional investors.

Bruker Price Performance

NASDAQ:BRKR opened at $56.85 on Wednesday. The stock has a market capitalization of $8.66 billion, a PE ratio of -81.21, a P/E/G ratio of 1.74 and a beta of 1.28. Bruker Corporation has a 1-year low of $28.53 and a 1-year high of $65.30. The firm has a fifty day simple moving average of $58.69 and a 200 day simple moving average of $47.71. The company has a current ratio of 1.85, a quick ratio of 0.92 and a debt-to-equity ratio of 0.76.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings results on Tuesday, August 4th. The medical research company reported $0.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.38 by $0.11. The firm had revenue of $838.50 million for the quarter, compared to analyst estimates of $853.57 million. Bruker had a negative net margin of 2.35% and a positive return on equity of 12.47%. The company’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.32 earnings per share. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, research analysts expect that Bruker Corporation will post 2.12 EPS for the current fiscal year.

Bruker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Monday, September 21st will be paid a $0.05 dividend. This represents a $0.20 annualized dividend and a yield of 0.4%. The ex-dividend date is Monday, September 21st. Bruker’s dividend payout ratio (DPR) is -28.57%.

Wall Street Analyst Weigh In

Several research analysts recently commented on the stock. UBS Group set a $60.00 target price on shares of Bruker in a report on Wednesday, June 24th. Leerink Partners lifted their price target on shares of Bruker from $60.00 to $70.00 and gave the company an “outperform” rating in a research note on Tuesday, July 7th. Wall Street Zen raised shares of Bruker from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. TD Cowen restated a “hold” rating on shares of Bruker in a research note on Wednesday, July 15th. Finally, Wolfe Research began coverage on Bruker in a report on Monday, June 1st. They issued a “peer perform” rating for the company. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Bruker has a consensus rating of “Moderate Buy” and an average target price of $56.64.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.